FDA Staff Raises Concerns Over Lack of Safety Data for Sickle-Cell Treatment
(Bloomberg) -- The Food and Drug Administration’s staff raised concerns about safety data on a potential gene-editing treatment for sickle cell disease, ahead of a closely watched meeting where scientific experts will weigh the first therapy using Crispr technology. Most Read from BloombergHouse Speaker Mike Johnson’s First Big Bill Cuts Biden’s Climate Change FundingUS Military Attacks Two Syrian Facilities It Says Linked to IranIsrael Latest: US Strikes Two Iran-Linked Fac...
United States Bloomberg Businessweek Fiona Rutherford Vertex Pharmaceuticals Inc American Society Of Hematology Drug Administration
Source: yahoo.com